Premium
Oral antiplatelet therapy in PCI patients
Author(s) -
Sharma Samin K.
Publication year - 2010
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.22367
Subject(s) - medicine , conventional pci , percutaneous coronary intervention , aspirin , coronary artery disease , pharmacotherapy , cardiology , clopidogrel , acute coronary syndrome , platelet aggregation inhibitor , myocardial infarction
Abstract The use of percutaneous coronary intervention (PCI) in the treatment of obstructive coronary artery disease has expanded rapidly in the past decade. Despite the extensive technological advancements in the field, pharmacotherapy has remained a cornerstone in the overall treatment strategy. Oral antiplatelet therapy has become an essential component of therapy with acute coronary syndromes and in PCI by improving clinical outcomes. This article reviews the antiplatelet options for patients undergoing PCI, including aspirin, ADP receptor blockers, and glycoprotein IIb/IIIa inhibitors. © 2010 Wiley‐Liss, Inc.